DR. ALLISON ELAINE GORREBEECK MD NPI 1467548628

NPI Details

DR. Allison Elaine Gorrebeeck, MD is a hematology and oncology internal medicine in Austin, TX with 26 years of experience. The provider is an internist doctor of osteopathy that specializes in the treatment of the combination of hematology and oncology disorders. A doctor of osteopathy that is board eligible/certified by the American Osteopathic Board of Internal Medicine WAS able to obtain a Certificate of Special Qualifications in the field of Hematology and Oncology. The Certificate is NO longer offered. DR. Allison Elaine Gorrebeeck, MD NPI is 1467548628. The provider is registered as an individual entity type.

The NPPES NPI record indicates the provider is a female.

Education
Medical School: UNIVERSITY OF TEXAS MEDICAL SCHOOL AT HOUSTON
Graduation Year:2000

The provider's business location address is:

12221 RENFERT WAY STE 300
AUSTIN, TX
ZIP 78758
Phone: (512) 873-8900
Fax: (512) 834-8676

The NPI 1467548628 is registered in the Medicare Provider, Enrollment, Chain and Ownership System (PECOS). The provider is legally eligible to order and refer Part B (Clinical Laboratory and Imaging), Durable Medical Equipment, Part A Home Health Agency (HHA), Power Mobility Devices.

The following top HCPCS codes were publicly reported for this provider under the Medicare program for the year 2016. The reported codes are based on the top codes for each available Medicare specialty, excluding evaluation and management codes.

• Injection, fosaprepitant, 1 mg (HCPCS:J1453)
• Injection, paclitaxel, 1 mg (HCPCS:J9267)
• Injection, iron sucrose, 1 mg (HCPCS:J1756)
• Injection, ferumoxytol, for treatment of iron deficiency anemia, 1 mg (non-esrd use) (HCPCS:Q0138)
• Injection, oxaliplatin, 0.5 mg (HCPCS:J9263)
• Injection, pembrolizumab, 1 mg (HCPCS:J9271)
• Injection, dexamethasone sodium phosphate, 1 mg (HCPCS:J1100)
• Injection, palonosetron hcl, 25 mcg (HCPCS:J2469)
• Injection, trastuzumab-anns, biosimilar, (kanjinti), 10 mg (HCPCS:Q5117)
• Injection, atropine sulfate, 0.01 mg (HCPCS:J0461)
• Injection, granisetron hydrochloride, 100 mcg (HCPCS:J1626)
• Injection of additional new drug or substance into vein (HCPCS:96375)
• Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count (HCPCS:85025)
• Insertion of needle into vein for collection of blood sample (HCPCS:36415)
• Blood test, comprehensive group of blood chemicals (HCPCS:80053)
• Injection, carboplatin, 50 mg (HCPCS:J9045)
• Injection, irinotecan, 20 mg (HCPCS:J9206)
• Injection, fluorouracil, 500 mg (HCPCS:J9190)
• Administration of chemotherapy into vein, 1 hour or less (HCPCS:96413)
• Injection, magnesium sulfate, per 500 mg (HCPCS:J3475)
• Established patient office or other outpatient visit, 40-54 minutes (HCPCS:99215)
• Immunologic analysis for detection of tumor antigen, quantitative; ca 15-3 (HCPCS:86300)
• Injection, cisplatin, powder or solution, 10 mg (HCPCS:J9060)
• Established patient office or other outpatient visit, 30-39 minutes (HCPCS:99214)
• Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less (HCPCS:96367)
• Oncology care model (ocm) monthly enhanced oncology services (meos) payment for ocm enhanced services. g9678 payments may only be made to ocm practitioners for ocm beneficiaries for the furnishment of enhanced services as defined in the ocm participation a (HCPCS:G9678)
• Administration of chemotherapy into vein, each additional hour (HCPCS:96415)
• Injection, potassium chloride, per 2 meq (HCPCS:J3480)
• Infusion, normal saline solution , 1000 cc (HCPCS:J7030)
• Administration of additional new drug or substance into vein, 1 hour or less (HCPCS:96417)
• Magnesium level (HCPCS:83735)
• Injection, diphenhydramine hcl, up to 50 mg (HCPCS:J1200)
• Established patient office or other outpatient visit, 20-29 minutes (HCPCS:99213)
• Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less (HCPCS:96365)
• Injection, zoledronic acid, 1 mg (HCPCS:J3489)
• Infusion into a vein for hydration, each additional hour (HCPCS:96361)
• Iron level (HCPCS:83540)
• Iron binding capacity (HCPCS:83550)
• Ferritin (blood protein) level (HCPCS:82728)
• Infusion into a vein for hydration, 31-60 minutes (HCPCS:96360)
• Lactate dehydrogenase (enzyme) level (HCPCS:83615)
• Gammaglobulin (immune system protein) measurement (HCPCS:82784)
• Injection of drug or substance under skin or into muscle (HCPCS:96372)
• Unclassified drugs (HCPCS:J3490)
• Microscopic examination for white blood cells with manual cell count (HCPCS:85007)
• Complete blood cell count (red cells, white blood cell, platelets), automated test (HCPCS:85027)
• Reticulated (young) platelet measurement (HCPCS:85055)
• Measurement of immunoglobulin light chains (HCPCS:83521)
• Infusion into a vein for therapy, prevention, or diagnosis concurrent with another infusion (HCPCS:96368)
• Leuprolide acetate (for depot suspension), 7.5 mg (HCPCS:J9217)
• New patient office or other outpatient visit, 60-74 minutes (HCPCS:99205)
• Chemotherapy administration, intravenous infusion technique; initiation of infusion in the office/clinic setting using office/clinic pump/supplies, with continuation of the infusion in the community setting (e.g., home, domiciliary, rest home or assisted l (HCPCS:G0498)
• Infusion into a vein for therapy, prevention, or diagnosis, each additional hour (HCPCS:96366)
• Carcinoembryonic antigen (cea) protein level (HCPCS:82378)
• Administration of hormonal anti-neoplastic chemotherapy under skin or into muscle (HCPCS:96402)
• Blood test, thyroid stimulating hormone (tsh) (HCPCS:84443)
• New patient office or other outpatient visit, 45-59 minutes (HCPCS:99204)
• Administration of additional new drug or substance into vein using push technique (HCPCS:96411)
• Follow-up hospital inpatient care per day, typically 25 minutes (HCPCS:99232)
• Beta-2 microglobulin (protein) level (HCPCS:82232)
• Protein measurement, serum (HCPCS:84165)
• Immunologic analysis technique on serum (HCPCS:86320)
• Immunologic analysis technique on serum (immunofixation) (HCPCS:86334)
• Irrigation of implanted venous access drug delivery device (HCPCS:96523)
• Follow-up hospital inpatient care per day, typically 35 minutes (HCPCS:99233)
• Blood test, basic group of blood chemicals (calcium, total) (HCPCS:80048)
• Cyanocobalamin (vitamin b-12) level (HCPCS:82607)
• Injection, tixagevimab and cilgavimab, for the pre-exposure prophylaxis only, for certain adults and pediatric individuals (12 years of age and older weighing at least 40kg) with no known sars-cov-2 exposure, who either have moderate to severely compromise (HCPCS:M0220)
• Red blood count, automated test (HCPCS:85045)
• Infusion, normal saline solution, sterile (500 ml = 1 unit) (HCPCS:J7040)
• Manual urinalysis test with examination using microscope, non-automated (HCPCS:81000)
• Folic acid level, serum (HCPCS:82746)
• Thyroxine (thyroid chemical), free (HCPCS:84439)
• Thyroid hormone, t3 measurement, free (HCPCS:84481)
• Drawing of blood for a medical problem (HCPCS:99195)
• Fluorodeoxyglucose f-18 fdg, diagnostic, per study dose, up to 45 millicuries (HCPCS:A9552)
• Administration of influenza virus vaccine (HCPCS:G0008)
• Influenza vaccine, quadrivalent inactivated, 0.5 ml dosage (HCPCS:90694)
• Nuclear medicine study from skull base to mid-thigh with ct scan (HCPCS:78815)

The enumeration date for this NPI number is 10/5/2006 and was last updated on 11/8/2018.

Taxonomy Codes

The NPI record includes the healthcare provider taxonomy classification, state license number and state of licensure. The following information regarding the scope of practice of this provider is available:

Other Identifiers

The following information regarding additional identifiers associated to this NPI record includes the other identifier number, identifier type, identifier state and issuer.